28
nanotimes
Companies Facts
MagForce has revised its corporate strategy to put more emphasis on clinical development and its synergies with Marketing and Sales. The company has received EU approval for its technology, Nano- Therm®
• US$1m milestone payment for achieving speci- fication targets for green quantum dots including a 50,000 hour performance life;
therapy, for the treatment of brain tumors.
Product revenues in 2011 were lower than expected due to the lack of involvement among leading me- dical experts in the development of the therapy. MagForce is now working closely with these key opinion leaders who have agreed to participate in a post-approval multi-center study to validate the novel technology in the medical community and gain first-hand experience.
“Our successful capital increase earlier this month along with reductions in expenditures will allow us to initiate both a glioblastoma post-market authori- zation study along with a study in prostate carcino- ma this year. These upcoming trials, conducted in centers throughout Germany, will lay the foundation for wider acceptance of the therapy and expanded commercial use,” said Dr. Andreas Jordan, Manage- ment Board and founder of MagForce. “In addition, we are in discussion with international companies and investors for strategic partnerships to share in the development costs and support international market approvals, including for the US market.”
http://www.magforce.com N
anoco Group plc (AIM: NANO), a developer and manufacturer of cadmium-free quantum
dots and other nanomaterials, announced its interim results for the six months ended 31 January 2012. Highlights in the period to date:
• Joint development agreement signed with one of the world’s largest lighting companies for use of Nanoco quantum dots in general lighting;
• Further agreement signed with Tokyo Electron in the next phase of development of a nanomaterial- based solar film;
• Joint development agreement signed with major Asian electronics company for the use of Nanoco quantum dots in the LED backlighting of LCD displays;
• Manufacturing scale-up continued with planning permission granted for the Kilo Lab facility at Runcorn;
• Cash, cash equivalents and deposits as at January 31, 2012 of £14.4 million (July 31, 2011: £17.1 million).
Commenting on the results, Dr Peter Rowley, Nanoco’s Chairman, said: “Our transition from a research-based company to a commercially focused, high-tech manufacturing business continues apace. Our existing commercial agreements are proceeding well and we continue in discussions with further potential customers. We are now working to deliver a 1kg batch of green quantum dots to a Japanese customer, attracting a US$2 million milestone pay- ment.”
12-03 :: March/April 2012
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79